Pegbelfermin
As of the edition of 20 October 2026, Pegbelfermin is a protein: stopped in 2021; acts on FGF1 and KLB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Protein
- Registered trials
- 12, 1 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2014 to now |
| Meridian Bioscience | Lead sponsor of trials | 2018 to now |